The Library

Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi district, Kenya

Tools

Nokes, D. James, Okiro, Emelda A., Ngama, Mwanajuma, Ochola, Rachel, White, Lisa J., Scott, P. D. (Paul D.), English, M. (Mike), Cane, Patricia and Medley, Graham. (2008) Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi district, Kenya. Clinical Infectious Diseases, Vol.46 (No.1). pp. 50-57. ISSN 1058-4838

Full text not available from this repository.

Official URL: http://dx.doi.org/10.1086/524019

Abstract

Background. In developing countries, there are few data that characterize the disease burden attributable to respiratory syncytial virus (RSV) and clearly define which age group to target for vaccine intervention.

Methods. Six hundred thirty-five children, recruited during the period 2002-2003, were intensively monitored until each experienced 3 epidemics of RSV infection. RSV infection was diagnosed using immunofluorescence of nasal washing specimens collected at each episode of acute respiratory infection. Incidence estimates were adjusted for seasonality of RSV exposure.

Results. For 1187 child-years of observation (CYO), a total of 409 (365 primary and 82 repeat) episodes of RSV infection were identified. Adjusted incidence estimates of lower respiratory tract infection (LRTI), severe LRTI, and hospital admission were 90 cases per 1000 CYO, 43 cases per 1000 CYO, and 10 cases per 1000 CYO, respectively, and corresponding estimates among infants were 104 cases per 1000 CYO, 66 cases per 1000 CYO, and 13 cases per 1000 CYO, respectively. The proportion of cases of all-cause LRTI, and severe LRTI and hospitalizations attributable to RSV in the cohort was 13%, 19%, and 5%, respectively. Fifty-five percent to 65% of RSV-associated LRTI and severe LRTI occurred in children aged > 6 months. The risk of RSV disease following primary symptomatic infection remained significant beyond the first year of life, and one-quarter of all reinfections were associated with LRTI.

Conclusions. RSV accounts for a substantial proportion of the total respiratory disease in this rural population; we estimate that 85,000 cases of severe LRTI per year occur in infants in Kenya. The majority of this morbidity occurs during late infancy and early childhood-ages at which the risk of disease following infection remains significant. Disease resulting from reinfection is common. Our results inform the debate on the target age group and effectiveness of a vaccine.

Item Type:

Journal Article

Subjects:

Q Science > QR Microbiology > QR355 Virology
R Medicine > RC Internal medicine
R Medicine > RJ Pediatrics

Divisions:

Faculty of Science > Life Sciences (2010- )

Library of Congress Subject Headings (LCSH):

Respiratory syncytial virus -- Kenya, Virus diseases in children -- Kenya, Respiratory syncytial virus -- Vaccination -- Kenya, Virus diseases in children -- Vaccination -- Kenya, Vaccination of children -- Kenya, Cohort analysis

Journal or Publication Title:

Clinical Infectious Diseases

Publisher:

University of Chicago Press

ISSN:

1058-4838

Official Date:

1 January 2008

Dates:

Date	Event
1 January 2008	Published

Volume:

Vol.46

Number:

No.1

Number of Pages:

Page Range:

pp. 50-57

Identification Number:

10.1086/524019

Status:

Peer Reviewed

Publication Status:

Published

Access rights to Published version:

Restricted or Subscription Access

Funder:

Wellcome Trust (London, England)

Grant number:

061584 (WT), 076278 (WT)

References:

1. Polack FP, Karron RA. The future of respiratory syncytial virus vaccine
development. Pediatr Infect Dis J 2004; 23:S65–73.
2. Venkatesh MP, Weisman LE. Prevention and treatment of respiratory
syncytial virus infection in infants: an update. Expert Rev Vaccines
2006; 5:261–8.
3. Karron RA,Wright PF, Belshe RB, et al. Identification of a recombinant
live attenuated respiratory syncytial virus vaccine candidate that is
highly attenuated in infants. J Infect Dis 2005; 191:1093–104.
4. Glezen W, Taber L, Frank A, Kasel J. Risk of primary infection and
reinfection with respiratory syncytial virus. Am J Dis Child 1986; 140:
543–6.
5. Melero JA, Garcia-Barreno B, Martinez I, Pringle CR, Cane PA. Antigenic
structure, evolution and immunobiology of human respiratory
syncytial virus attachment (G) protein. J Gen Virol 1997; 78:2411–8.
6. Gomes MG, White LJ, Medley GF. Infection, reinfection, and vaccination
under suboptimal immune protection: epidemiological perspectives.
J Theor Biol 2004; 228:539–49.
7. Selwyn B; Coordinated Data Group of BOSTID Researchers. The epidemiology
of acute respiratory tract infection in young children: comparison
of findings from several developing countries. Rev Infect Dis
1990; 12(Suppl 8):S870–88.
8. Broor S, Parveen S, Bharaj P, et al. A prospective three-year cohort
study of the epidemiology and virology of acute respiratory infections
of children in rural India. PLoS ONE 2007; 2:e491.
9. Robertson SE, Roca A, Alonso P, et al. Respiratory syncytial virus
infection: denominator-based studies in Indonesia, Mozambique, Nigeria
and South Africa. Bull World Health Organ 2004; 82:914–22.
10. Stensballe LG, Devasundaram JK, Simoes EA. Respiratory syncytial
virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect
Dis J 2003; 22:S21–32.
11. Weber M, Mulholland E, Greenwood B. Respiratory syncytial virus
infection in tropical and developing countries. Trop Med Int Health
1998; 3:268–80.
12. Nokes DJ. Respiratory syncytial virus disease burden in the developing
world. In: Cane PA, ed. Perspectives in medical virology: respiratory
syncytial virus. Vol. 14. Amsterdam: Elsevier, 2007:183–230.
13. Nokes DJ, Okiro EA, Ngama M, et al. Respiratory syncytial virus epidemiology
in a birth cohort from Kilifi District, Kenya: infection during
the first year of life. J Infect Dis 2004; 190:1828–32.
14. Ministry of Finance and Planning. Analytical report on population
projections. Vol. VII. Central Bureau of Statistics. Nairobi, Kenya: Central
Bureau of Statistics, Government of Kenya, 2002.
15. Mwangi TW, Ross A, Snow RW, Marsh K. Case definitions of clinical
malaria under different transmission conditions in Kilifi District,
Kenya. J Infect Dis 2005; 191:1932–9.
16. Cowgill KD, Ndiritu M, Nyiro J, et al. Effectiveness of Haemophilus
influenzae type b conjugate vaccine introduction into routine childhood
immunization in Kenya. JAMA 2006; 296:671–8.
17. Hall C, Douglas RJ. Clinically useful method for the isolation of respiratory
syncytial virus. J Infect Dis 1975; 131:1–5.
18. Henderson F, Collier A, Clyde WJ, Denny F. Respiratory-syncytialvirus
infections, reinfections and immunity: a prospective, longitudinal
study in young children. N Engl J Med 1979; 300:530–4.
19. Freymuth F, Vabret A, Galateau-Salle F, et al. Detection of respiratory
syncytial virus, parainfluenzavirus 3, adenovirus and rhinovirus sequences
in respiratory tract of infants by polymerase chain reaction
and hybridization. Clin Diagn Virol 1997; 8:31–40.
20. Collins PL, Chanock RM, Murphy BR. Respiratory syncytial virus. In:
Knipe DM, Howley PM, eds. Fields virology. Philadelphia, PA: Lippincott-
Raven, 2001:1443–85.
21. World Health Organization. Pocket book for hospital care of children:
guidelines for the management of common illness with limited resources.
Geneva: World Health Organization, 2005.
22. Fisher RG, Gruber WC, Edwards KM, et al. Twenty years of outpatient
respiratory syncytial virus infection: a framework for vaccine efficacy
trials. Pediatrics 1997; 99:E7.
23. Englund J, Glezen WP, Piedra PA. Maternal immunization against viral
disease. Vaccine 1998; 16:1456–63.